An industry leading iPSC-based drug discovery platform
Evotec has built an industrialised iPSC infrastructure that represents one of the largest and most sophisticated iPSC platforms in the industry. Evotec's iPSC platform has been developed over the last six years with the goal to industrialise iPSC-based drug screening in terms of throughput, reproducibility and robustness to reach the highest industrial standards. This effort was initially enabled by a research collaboration and licence agreement with Harvard University involving world-leading scientists at the Harvard Stem Cell Institute. More recently, Evotec has established collaborations with Celgene, Sanofi, DFG Research Center for Regenerative Therapies Dresden, Censo Biotechnologies and Fraunhofer IME-SP to support Evotec's broad iPSC platform. In addition, we are working together with a number of academic institutions to further broaden and strengthen our iPSC ambitions.